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Abstract
The bacterial growth environment within cystic fibrosis (CF) sputum is complex, dynamic,
and shaped by both host and microbial processes. Characterization of the chemical param-
eters within sputum that stimulate the in vivo growth of airway pathogens (e.g. Pseudomo-
nas aeruginosa) and their associated virulence factors may lead to improved CF treatment
strategies. Motivated by conflicting reports of the prevalence and abundance of P. aerugi-
nosa-derived metabolites known as phenazines within CF airway secretions, we sought to
quantify these metabolites in sputum using quadrupole time-of-flight mass spectrometry. In
contrast to our previous work, all phenazines tested (pyocyanin (PYO), phenazine-1-car-
boxylic acid (PCA), phenazine-1-carboxamide, and 1-hydroxyphenazine) were below detec-
tion limits of the instrument (0.1 μM). Instead, we identified a late-eluting compound that
shared retention time and absorbance characteristics with PCA, yet generated mass spec-
tra and a fragmentation pattern consistent with ferriprotoporphyrin IX, otherwise known as
heme B. These data suggested that UV-vis chromatographic peaks previously attributed to
PCA and PYO in sputum were mis-assigned. Indeed, retrospective analysis of raw data
from our prior study found that the heme B peak closely matched the peaks assigned to
PCA, indicating that the previous study likely uncovered a positive correlation between pul-
monary function (percent predicted forced expiratory volume in 1 second, or ppFEV1) and
heme B, not PCA or any other phenazine. To independently test this observation, we per-
formed a new tandem mass-spectrometry analysis of 71 additional samples provided by the
Mountain West CF Consortium Sputum Biomarker study and revealed a positive correlation
(ρ = −0.47, p<0.001) between sputum heme concentrations and ppFEV1. Given that
hemoptysis is strongly associated with airway inflammation, pulmonary exacerbations and
impaired lung function, these new data suggest that heme B may be a useful biomarker of
CF pathophysiology.
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Introduction
Pseudomonas aeruginosa lung infections are a leading cause of morbidity and mortality in cys-
tic fibrosis (CF) patients [1, 2]. Our laboratory has studied a class of small molecules produced
by P. aeruginosa known as phenazines, including pyocyanin and its biogenic precursor phena-
zine-1-carboxylic acid (PCA). As phenazines are known virulence factors [3], we and others
have explored the possibility of using phenazine concentrations as a marker for disease pro-
gression [4–6]. Previously, we reported that sputum concentrations of pyocyanin and PCA
negatively correlate with lung function in CF patients [6]. Our study used high performance
liquid chromatography (HPLC) to quantify phenazines by UV–vis absorbance after extraction
from sputum.
Since our initial study, methods for metabolite analysis have advanced considerably,
aided in large part by usage of mass spectrometry (LC-MS) and tandem mass spectrometry
(LC-MS/MS). Because a more recent study employing LC-MS/MS revealed a surprising
decoupling of P. aeruginosa metabolites in sputum and the detection of P. aeruginosa
through culturing or microbiome profiles [4], we decided to check whether we could repro-
duce our previous findings by analyzing sputum samples from a different patient cohort
with a new LC-MS instrument in our laboratory. New samples were provided by the Moun-
tain West CF Consortium Sputum Biomarker study [7]. In the course of performing our
new analyses, comparison of our old HPLC data to our new LC-MS data led us to realize
that the peak previously assigned to PCA instead originates from heme, and the peak
assigned to pyocyanin originates from an as-yet unknown compound. Here we present new
data showing that heme concentration positively correlates with lung function decline in
CF patients.
Results
Identification of heme in sputum
Motivated by a recent LC-MS/MS study that reported phenazines in only a fraction of samples
that were sequence-positive for P. aeruginosa [4], we sought to determine whether we could
repeat our previously reported correlation between phenazines and disease progression (mea-
sured by percent predicted forced expiratory volume in 1 second, or ppFEV1). We obtained
fresh sputum samples from the Mountain West CF Consortium (MWCFC) sputum biomarker
study and analyzed 71 sputum supernatants using HPLC coupled to UV–vis detection and a
single quadrupole mass spectrometer (Waters Acquity QDa). Patients with confirmed CF
enrolled in the MWCFC study were randomly selected from all sputum producers older than
twelve years of age and enrolled during clinical stability (Table 1). Selected patients had a
mean age of 27 years (SD = 13), ppFEV1 of 68% (SD = 23), and weight-for-age z-score of
−0.17 (SD = 0.96) at the time of enrollment. Patients had a median of 2.0 pulmonary exacerba-
tions in the year prior to enrollment (range 0–6), diabetes in 24%, pancreatic sufficiency in
9.9% and 5-year survival predictions [8] ranging from 9.4% to>99% (median 95%). There
were no significant differences in clinical characteristics, microbiology or treatment profiles
between patients with and without heme measurement results from the greater MWCFC
patient cohort (Table 1), strongly suggesting that missing heme measurements were missing at
random [9] and that inferences based on the measurements made are not biased due to a spe-
cific pattern of patient selection. As previously reported, there were no differences between the
characteristics of the 114 patients in the MWCFC study group and the other 14,394 patients
twelve years of age and able to produce sputum found in the 2014 CF Foundation Patient Reg-
istry [7].
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To our surprise, and in contrast to our prior study, we were unable to detect the phenazines
pyocyanin, PCA, phenazine-1-carboxamide, or phenazine-1-hydroxide in any of the samples
within our detection limit (approximately 0.1 μM) in either the UV–vis or mass channels.
Instead, we observed a late-eluting compound in all 71 samples which had an absorbance spec-
trum that overlaps with the phenazine spectrum but is distinguished by a maximum at 398
nm. This compound produced positive ions at an m/z of 616.2, further distinguishing it from
any known phenazine, and it was present even in patients who were culture-negative for P.
aeruginosa. We noted a striking similarity between the UV–vis spectrum of this compound
with published spectra for the porphyrin ring of heme-like compounds [10]. We therefore
wondered whether this peak represented a compound related to heme, and whether we might
have mis-assigned it previously in sputum samples, which are more chemically complex than
bacteriological media.
To further interrogate the peak, we transferred our method to an instrument coupled to a
high-resolution quadrupole time-of-flight mass spectrometer (Waters Xevo). Again we
Table 1. Patient cohort characteristics.
Patient Characteristics, Infections and Treatmentsa Heme Result Obtained
n = 71
Heme Measurement Not Performed
n = 43
p-value
Male sexb 30 (0.42) 23 (0.53) 0.25
Age, Years (SD)c 27 (13) 30 (11) 0.21
ppFEV1, Percent Predicted (SD)
c 68 (23) 74 (21) 0.17
Weight-for-age z-score (SD)c -0.17 (0.96) -0.18 (1) 0.96
Pulmonary exacerbations in year prior to enrollmentd median (range) 2 (0–6) 2 (0–7) 0.056
Height, cmc 167 (10.2) 167 (9.62) 0.64
5-Year Predicted Survivald 0.95 (0.094->0.99) 0.97 (0.34->0.99) 0.14
Diabetesb 17 (0.24) 8 (0.19) 0.66
Pancreatic Sufficiencyb 7 (0.099) 2 (0.047) 0.52
CF related arthropathyb 4 (0.056) 4 (0.093) 0.72
Methicillin Sensitive S. aureusb 34 (0.48) 17 (0.40) 0.5
Methicillin Resistant S. aureusb 14 (0.2) 7 (0.16) 0.83
P. aeruginosab 45 (0.63) 25 (0.58) 0.72
B. cepacia complexb 2 (0.028) 1 (0.023) >0.99
S. maltophiliab 4 (0.056) 3 (0.07) >0.99
Achromobacter sppb 3 (0.042) 2 (0.047) >0.99
Candida sppb 14 (0.2) 3 (0.07) 0.11
Aspergillus sppb 10 (0.14) 2 (0.047) 0.2
MAI complexb 0 (0) 1 (0.023) 0.8
M. abscessusb 0 (0) 3 (0.07) 0.8
Patients on inhaled tobramycinb 21 (0.30) 17 (0.40) 0.37
Patients on inhaled aztreonamb 27 (0.38) 13 (0.30) 0.52
Patients on daily oral azithromycinb 39 (0.55) 23 (0.53) >0.99
Patients on inhaled hypertonic salineb 41 (0.58) 30 (0.70) 0.28
Patients on inhaled DNaseb 64 (0.90) 37 (0.86) 0.72
a Data are presented as counts (fraction affected), mean (SD) or median (range) as appropriate for the variable and distribution of values. See other footnotes for specific
annotations.
b Number of patients affected (fraction affected).
c Mean (SD) for variables with normal distribution.
d Median (Range) for variables with non-normal distribution.
https://doi.org/10.1371/journal.pone.0226578.t001
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consistently observed a UV–vis chromatographic peak at 398 nm (Fig 1A). Consistent with its
identity as a heme, this peak had a retention time identical to that of a hemin standard (Fig
1A). Both the sputum samples and the hemin standard gave an equivalent peak in the extracted
ion chromatogram for an m/z of 616.1773 ± 0.01 (Fig 1A), the m/z expected for hemin having
lost its associated chloride ion to produce ferriprotoporphyrin IX. We note that the hemin
standard was dissolved in base, a condition known to replace the chloride ion with hydroxide
[11] which is subsequently removed in the acidic conditions of our chromatography, therefore
explaining the origin of ferriprotoporphyrin IX from our hemin standard. In the positive ion
channel (Fig 1B), sputum and hemin produced equivalent signals that were indistinguishable
from the expected mass of ferriprotoporphyrin IX within the resolution of the instrument
(Δppm = 0.97 and −1.6, respectively). Similarly, in the negative channel (Fig 1C), both sputum
and hemin produced ions consistent with the formic acid adduct of ferriprotoporphyrin IX
(Δppm = −0.45 and 0.45, respectively), an additive used in our separation method. Application
of collision energy produced equivalent fragmentation patterns in the negative ion mode (Fig
1C) with the major daughter ion appearing around 570.1718, consistent with two decarboxyl-
ations or a single decarboxylation and loss of formic acid. The sputum peak and the hemin
standard also produced indistinguishable UV−vis spectra (Fig 1D) which closely matched pre-
vious reports for heme [10]. Based on identical retention times, mass and UV–vis spectra, and
mass fragmentation patterns, we assign this peak to ferriprotoporphyrin IX, also known as
heme B (Fig 1E).
Fig 1. Identification of heme in sputum samples by comparing sputum (black) to a hemin standard (green). (A) UV–vis chromatogram (top)
and extracted ion chromatogram (616.1773 ± 0.01 Da) from the positive mass channel (bottom) demonstrating identical retention times. (B) The
associated positive ions detected from the peak shown in A, comparing the sputum peak (top) to the hemin standard (bottom). (C) The associated
negative ions detected from the peak shown in B, comparing the sputum peak (top) to the hemin standard (bottom). A collision-energy ramp of 10
to 14 eV was applied to generate a fragmentation pattern. (D) Comparison of the UV–vis spectra for the peaks in A (black and green) compared to
the same peak identified in our prior study (gray, dashed). For clarity, the spectra are normalized to their maximum value. (E) The chemical
structure assigned to the peak in A, ferriprotoporphyrin IX.
https://doi.org/10.1371/journal.pone.0226578.g001
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Re-analysis of the original data
Though the MWCFC cohort differed in inclusion criteria from that used in our prior Chil-
dren’s Hospital Boston (CHB) sputum study (i.e. a positive diagnosis of CF based on genotyp-
ing or sweat test and positive P. aeruginosa culture), we were nevertheless surprised that we
were unable to detect phenazines in the MWCFC samples with our newer instrument. At the
time of our previous analysis, we were using an older HPLC instrument equipped with UV–
vis detection but not mass detection, and so we became concerned that we may have mis-iden-
tified other compounds as phenazines using this older instrument and decided to revisit our
old raw data. In the CHB study, we employed a standard protocol, used by our group and oth-
ers for routine phenazine analysis in bacteriological cultures, which detects phenazines by
their retention times in UV–vis chromatograms (387 nm for pyocyanin and 364 nm for PCA).
We used this method to quantify phenazine production from 779 clinical isolates of P. aerugi-
nosa from CF sputum from 47 CHB patients [6]. Re-examination of the raw data confirmed
appropriate phenazine assignment in samples from pure cultures of P. aeruginosa. To quantify
phenazines in CF sputum, we co-injected pyocyanin or PCA into sputum from which we
could not culture P. aeruginosa (a major source of phenazines in CF patients) and ran standard
curves. In these control co-injection samples, we observed distinct HPLC peaks at 387 nm and
364, as would be expected for pyocyanin or PCA, respectively. Accordingly, we used absorp-
tion at these wavelengths to quantify phenazines in all sputum samples. With the benefit of
our new awareness that heme B shares retention and absorption characteristics with PCA, we
revisited the complete spectral data for each peak from the raw data on our old HPLC, suspect-
ing that we might have unwittingly mis-assigned phenazines to other compounds in sputum.
Indeed, analysis of the full UV–vis spectra revealed that the sputum peak we had tracked at
364 nm and assigned to PCA had an absorbance maximum at 398 nm (Fig 2A), suggesting it is
unlikely to be PCA despite similar retention times and overlapping absorbance spectra.
Instead, this peak’s absorbance spectrum closely matched the spectrum of ferriprotoporphyrin
IX identified in our new study (Fig 1D), suggesting we had mis-assigned the heme peak as
PCA. Similarly, the sputum peak previously assigned to pyocyanin has an absorbance maxi-
mum around 360 nm (Fig 2B) instead of 387 nm, suggesting that pyocyanin is not the major
component of this peak. The early-eluting portion of the chromatogram that contains pyocya-
nin is crowded by multiple overlapping peaks with similar spectra, and so we have been unable
to characterize it further.
Despite our best efforts to perform appropriate controls, including co-injections, the UV–
vis spectra reveal that the peaks for pyocyanin and PCA were incorrectly assigned in the origi-
nal CHB study. This error stemmed from the co-elution of phenazines with sputum com-
pounds that have similar absorbance spectra and the lack of a MS system on the older HPLC
instrument. In addition, the older instrument produced significant retention time variability
between HPLC samples (up to ±1 minute for PCA), further masking the incorrect assignment.
While we cannot rule out the possibility that phenazines were present in our old samples, the
distinct UV–vis absorbance spectra indicate that phenazines were not the major component of
the assigned peaks, and so our original report overestimated the phenazine concentration in
CF sputum samples.
Heme concentrations correlate negatively with lung function
As the re-analysis suggests, the interpretation of our original HPLC data was confounded by
co-eluting compounds that are present in sputum. The similarity between the peak we previ-
ously analyzed as PCA and what we have now identified as ferriprotoporphyrin IX (Fig 1D)
suggests that, instead of a correlation between phenazines and ppFEV1, the original study
Sputum heme content and lung function decline
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measured a correlation between heme and ppFEV1. To evaluate this possibility, we quantified
the concentration of ferriprotoporphyrin IX in our MWCFC samples from our new dataset.
Heme concentrations in sputum were log-normal in distribution (Anderson-Darling test sta-
tistic 0.61, p = 0.11). Further, a plot of heme concentration versus ppFEV1 reveals a statistically
significant (Spearman’s ρ = −0.47, p< 0.001) correlation between sputum heme levels
and ppFEV1 (Fig 3). Although the concentration of ferriprotoporphyrin IX in the original
samples is unknown, it is likely that the original PCA concentration data instead represents
heme concentration with an unknown conversion factor, and so both studies have indepen-
dently confirmed a correlation between the heme signal in HPLC analysis and lung function
in CF patients.
Discussion
Several independent analyses have detected phenazines in sputum from CF patients [4, 5]. Our
new data collection effort and the correction reported here to our previous results [6] was par-
tially motivated by a more recent report of detectable phenazine concentrations in only 3 of 27
Fig 2. Re-analysis of HPLC peaks previously assigned as phenazines from original data collected on an older
HPLC. UV–vis chromatograms are shown on the left, and the full UV–vis spectra of the peaks indicated with an arrow
are shown on the right. Where indicated on the y-axis, the data have been normalized to bring the data into the same
scale for clarity. (A) Analysis of the PCA peak, comparing a pure PCA standard (chromatogram at 364 nm, orange) to
a sputum sample (chromatogram at 398 nm, black). (B) Analysis of the pyocyanin peak, comparing pyocyanin in P.
aeruginosa-free sputum (blue) to a P. aeruginosa-positive sputum sample (black) (both chromatograms at 387 nm).
https://doi.org/10.1371/journal.pone.0226578.g002
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patients [4]. Interestingly, extensive isolation of several hundred clinical P. aeruginosa strains
in our lab has verified that phenazine production is a nearly universal capability of P. aerugi-
nosa strains that inhabit CF patients, a result that is still valid from our original study [6]. All
phenazine analyses in the original paper that were performed in bacteriological growth
medium were accurate. We therefore find it interesting that phenazines and other P. aerugi-
nosa metabolites are detected only sporadically in sputum samples, often from patients that
are culture-negative for P. aeruginosa [4]. Together these findings are suggestive of significant
macro- and micro-scale heterogeneity within CF lungs. Consistent with regional heterogene-
ity, P. aeruginosa strains within different regions are known to undergo independent evolution
with minimal cross-colonization [12]. It is difficult to verify that independent samples origi-
nate from the same region of the lung, and so heterogeneity between sputum samples may
account for differences between metabolite and microbial analyses within the same patient.
Furthermore, sputum samples are extremely viscous and poorly mixed, leading to high spatial
heterogeneity within individual samples [13]. Sputum viscosity originates from extracellular
polymers including DNA [14], and because pyocyanin and other phenazines are known DNA
intercalators [15], it is likely that cells within the sputum matrix encounter a micro-scale phen-
azine concentration that is considerably higher than that determined by bulk measurements.
We anticipate that new methods to image metabolites at large and small spatial scales will pro-
vide insights into the CF lung environment and clarify the role of pathogen-derived metabo-
lites in disease progression. Although it remains possible that phenazine concentration
negatively correlates with lung function, our original study overestimated the total phenazine
concentration and the true bulk concentrations were likely below our limit of detection.
The form of heme we measured in this study, ferriprotoporphyrin IX or heme B, is the
most abundant heme found in humans and the oxygen-carrying component of hemoglobin in
Fig 3. Correlation between ferriprotoporphyrin IX concentration and disease status as measured by percent
predicted FEV1 (Spearman’s ρ = −0.47, p = 3.6 × 10−5). Each data point represents a single sputum sample from a
unique patient. The dashed line illustrates a linear regression through the data.
https://doi.org/10.1371/journal.pone.0226578.g003
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red blood cells. Given that the majority of components in lung sputum are host-derived [4],
the heme likely originated from blood rather than from microbial sources. Consistent with
this assumption, hemoptysis, or coughing up blood, is observed in up to 60% of CF patients
[16–18]. While minor blood streaking in sputum does not usually prompt treatment, massive
hemoptysis is a marker of pulmonary exacerbations and correlates with impaired lung func-
tion and mortality in adults [16, 17], and so the correlation between heme and lung function
decline may identify heme as a potentially useful biomarker of clinical disease in CF.
Previously we also reported a correlation between sputum iron and lung function decline
[19]. This correlation arose from the abundance of Fe(II) which predominated, rather than
from Fe(III) [19]. We also reported a correlation between Fe(II) and what we believed was
PCA [18], which we now recognize was heme. As heme is a major carrier of iron, this correla-
tion suggests blood-derived heme may be a significant source of sputum iron. In the context of
lung infections, iron is an important nutritional regulator of pathogenicity and biofilm forma-
tion in bacteria, including P. aeruginosa [20], and pathogenic bacteria can extract iron from
heme [10]. Given that iron chelation is now being explored as a potential therapy for lung
infections [21], there is a need to better understand the sources of sputum iron and its influx
rate, of which our results suggest host-derived heme could be a significant contributing factor.
The prognosis for CF patients has improved remarkably in recent decades, owing not only
to advances in treatments but also in diagnostics and preventative care [22]. While the role of
pathogen-derived metabolites in disease state is still uncertain, host-derived factors are clearly
abundant [4] and may provide new markers to guide treatment. The prevalence of heme in
every sputum sample we measured, and the simplicity of its detection by HPLC owing to its
characteristic 398 nm absorbance peak, suggest it can be a useful diagnostic component for
monitoring CF disease activity. Additional research may uncover a causative link between spu-
tum heme and lung disease through the interplay between iron and pathogenic microbes.
Materials and methods
HPLC method from the original study
The original study used a Beckman Gold HPLC equipped with preparative-scale pumps on a
model 126P solvent module. The separation used a Waters Symmetry C18 column with
dimensions 4.6 mm × 250 mm and a particle size of 5 μm. The injection volume was 100 μl,
supplied via a model 508 autosampler, and the flow rate was 1.0 mL/min. Solvent A was water
with 0.1% trifluoroacetic acid (TFA) and Solvent B was acetonitrile with 0.1% TFA. Com-
pounds were eluted using a linear gradient of 15% B from 0 to 2 minutes, 15% to 83% B from 2
to 22 minutes, and 0% B from 22 to 30 minutes. UV–vis data were collected from 200 to 600
nm using a model 168 photodiode array detector.
Sample preparation
Sputum samples were obtained after informed consent from patients with confirmed CF aged
12 and older able to expectorate sputum during clinical stability. The study protocol was
reviewed and approved at each of the 9 participating centers in the Mountain West CF Con-
sortium (MWCFC). To derive a sample of patients representative of all patients in the United
States who are 12 years of age and older and also produce sputum, we used the pseudo-random
number generator method [23] to randomly assign selection priorities to every eligible patient
in the MWCFC. After accounting for previously observed enrollment rates for observational
studies and rates of attendance at CF clinics in the region, we recruited patients according to
the randomly assigned priorities for the study. While maintaining randomization, we con-
trolled the rates of enrollment to reduce seasonal and center-specific biases by setting a
Sputum heme content and lung function decline
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threshold selection priority for recruitment by center. Detailed methods are provided in Liou
et al. [7].
Samples were processed within 4 hours of expectoration by dilution 1:1 with Hanks buff-
ered saline solution (Sigma, St Louis, MO), vigorous vortex mixing for 1 minute followed by
centrifugation at 2,800 g and 4˚C for 20 minutes to obtain lipid and aqueous fractions and pel-
lets. For this study, we used aqueous fractions that were mixed 1:1 with protease inhibitor
cocktail (Sigma). Fractions were frozen and stored at −80˚C until use. The samples were
thawed at room temperature and centrifuged at 13,000 g for 15 minutes. The supernatant was
transferred to a Waters Total Recovery Vial and injected directly into the HPLC without fur-
ther processing. Hemin was purchased from Sigma-Aldrich and was dissolved to a stock con-
centration of 10 mM using 100 mM aqueous ammonia. A standard curve from 0.01 to 100 μM
was created by diluting the stock solution into water.
Spirometry
Clinical data including spirometry data were collected at the same time as sputum samples.
The forced expiratory volume in 1 second (FEV1) was measured according to American Tho-
racic Society standards [24]. FEV1 was normalized to percent predicted FEV1 (ppFEV1) for
age, sex, height, race and ethnicity using NHANES III equations [25] as was done clinically at
all participating centers at the time of study enrollment.
High resolution LC-MS
HPLC separations for high resolution mass spectrometry were performed on a Waters Acquity
I-Class UPLC connected to a Waters Acquity PDA detector and a Waters Xevo G2-XS quadru-
pole time-of-flight mass spectrometer. The sample chamber was maintained at 4˚C. The sepa-
ration used a Waters XBridge BEH C18 XP column with dimensions 3.0 × 100 mm and a
particle size of 2.5 μm. The column was equipped with a VanGuard guard column comprising
the same resin. The injection volume was 5 μl and the flow rate was 0.5 mL/min. The column
was maintained at 40˚C. Solvent A was water with 0.1% formic acid and solvent B was acetoni-
trile with 0.1% formic acid. Compounds were eluted using a linear gradient of 0% to 90% from
0 to 24 minutes, 90% B from 24 to 25 minutes, and 0% B from 25 to 35 minutes. Mass scans
from 150 to 1000 Da were collected in separate chromatographic runs for positive and negative
ionization modes with a scan time of 0.3 s. For both modes, the mass spectrometry parameters
were: capillary voltage, 1.5 kV; sampling cone, 30 V; source offset, 80 V; source, 120˚C; deso-
lvation, 550˚C; cone gas, 50 L/h; desolvation gas, 800 L/h. The analyser mode was set to resolu-
tion and the dynamic range was set to normal. In the negative ion mode, fragmentation data
were collected in a second data channel using a collision-ramp energy of 10 to 14 eV. A solu-
tion of 20 pg/μL leucine enkephalin was used as the LockSpray solution with a flow rate of
20 μl/min. The instrument was controlled using the software MassLynx.
Routine LC-MS for ferriprotoporphyrin IX quantification
For routine analysis, HPLC separations were performed on a Waters Alliance HPLC con-
nected to a Waters 2998 PDA detector and a Waters Acquity QDa single quadrupole mass
spectrometer. The sample chamber was maintained at 10˚C. Separations were performed the
same as for the high-resolution method, except that the gradient included a constant 2% meth-
anol supplied via solvent C, which was found to greatly improve the reproducibility of pyocya-
nin measurements. Mass scans were collected simultaneously from 100 to 900 Da in the
positive mode and 100 to 600 Da in the negative mode. In addition, a selected ion recording
channel was collected in the positive mode for 211.09, 224.08, and 225.07 Da, the masses
Sputum heme content and lung function decline
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expected for pyocyanin, phenazine-1-carboxamide, phenazine-1-carboxylic acid, respectively.
The probe temperature was 600˚C and the capillary voltage was 0.8 kV. UV–vis data were col-
lected from 200 to 800 nm at 20 Hz with a resolution of 1.2 nm. The instrument was controlled
using the software Empower. Peaks representing ferriprotoporphyrin IX were integrated using
the Apex Track algorithm within Empower and compared against a linear calibration curve of
samples derived from hemin. The measured concentrations were multiplied four-fold to
account for the dilution that occurred during sample processing.
Data and statistical analysis
Observations of anticipated phenazine detections demonstrated non-detectability through the
first 71 samples that we analyzed, yet heme was detectable in each of those samples. Compari-
son of characteristics of the patients providing the tested samples with the remaining samples
showed that further measurements were unlikely to detect phenazines and change any inter-
pretations. Accordingly, no further samples were tested, as the tested group of patients was
representative of the whole MWCFC cohort and of the US population of sputum producers
(Table 1).
To ensure uniformity, data from the three instruments were exported and compared
together within a series of Python scripts. Plots were generated using the Matplotlib package
and labeled with Adobe Illustrator. The Spearman correlation coefficient was calculated using
the spearmanr function in the SciPy package. Assessments of normality were performed in R.
Human subjects
MWCFC work was reviewed and approved by the Investigational Review Board (IRB) of Uni-
versity of Utah (IRB_00011571), St. Luke’s Health System (13–0547), Billings (Study 14.07),
Western (for the Las Vegas CF Center) (1146159, WIRB PRO NUM: 20140721, INVEST
NUM: 112264, WO NUM: 1–837046–1, Protocol Number 20130530), National Jewish Health
(HS-2797), Colorado Multiple IRB (for Children’s Hospital Colorado) (13–3172), Phoenix
Children’s Hospital (13–087), University of Arizona (1407394040), and the University of New
Mexico (14–085). No patients were enrolled prior to IRB approval. All patients younger than
18 provided assent with informed written consent provided by parents or other legal guard-
ians. Each adult patient gave informed written consent on his or her own behalf. A detailed
description of patient recruitment is provided in Liou et al. [7].
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